Set trial enrolment targets from who actually gets the disease, and publish progress live
Each trial would set its target mix of patients from cancer registry data on who gets that cancer, by age, sex and ethnicity, and show a public running tally so gaps are visible while there is still time to fix them.
Sponsors derive enrolment targets per stratum from incidence data (SEER, GLOBOCAN, national registries) for the indication and the countries where the trial runs, publish the targets in the registry record, and update enrolled counts quarterly. Recruitment resources are reallocated during the trial toward under-enrolled strata (site additions, navigators, translated materials).
- Trials do not represent the people who get cancer · Older, Black, Hispanic, Asian, rural, poor and multimorbid patients are under-represented, so results may not apply to them.
- Trials enrol too few, too slowly · Fewer than one in ten adults with cancer joins a trial. Trials close for lack of patients, not lack of ideas.
Pages like this
not linked directly; found by shared links- IdeaA public map of trial deserts to steer where new sites open
Shares GLOBOCAN / Global Cancer Observatory, SEER (Surveillance, Epidemiology, and End Results), ClinicalTrials.gov, Trials do not represent the people who get cancer.
- IdeaRemote consent and tele-screening so the first trial visit is a video call
Shares Unger: most patients never get the chance to join a cancer trial, and when offered, half say yes, Trials enrol too few, too slowly.
- JournalCA: A Cancer Journal for Clinicians
Shares GLOBOCAN / Global Cancer Observatory, SEER (Surveillance, Epidemiology, and End Results).
- IdeaDefault-inclusive eligibility: sponsors must justify every exclusion criterion
Shares ClinicalTrials.gov, Trials do not represent the people who get cancer, Trials enrol too few, too slowly.
- IdeaPay oncologists for the time it takes to enrol a patient
Shares Unger: most patients never get the chance to join a cancer trial, and when offered, half say yes, Trials enrol too few, too slowly.
- IdeaA public tracker of how long each country takes to adopt new evidence
Shares GLOBOCAN / Global Cancer Observatory, SEER (Surveillance, Epidemiology, and End Results).
- IdeaPay trial participants for their time, not only their expenses
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly.
- IdeaTravel, lodging and meals reimbursed as a standard line in every trial budget
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly.